Page 401 - Control Theory in Biomedical Engineering
P. 401

368   Index


          Bipedal-compliant walking system, 7, 9f  Cardiovascular diseases (CVDs), 43–44
          Blood glucose concentration (BGC), 63  Cardiovascular system, 14–15
          Blood glucose regulation, 31      CAREX-7, 236–237, 239f, 248–251
          Blood vessels system, 7, 9f       CETP. See Cholesteryl ester transfer protein
          BLUE SABINO, 236–237, 240f             (CETP)
          BMI. See Body mass index (BMI)    Chaotic-cancer system, 17–18, 18f
          Body mass index (BMI), 52–54      Chaotic system, 15–18, 33
          Body-powered prosthesis, 212–213  Chemotherapy, 84–85, 89–90, 90f
          Bolus insulin, 71–73              Chihi’s handwriting model, 138t
                                            Chiral structure, 327–328, 329f, 336, 338f
                                            Cholesterol homeostasis
          C                                   absorption, 54–55
          CABexo, 236–237                     amplitude, 55–57
          CABXLexo-7, 236–237, 239f, 246,     de novo synthesis, 52, 56–57
                250–251                       diet, 56
          CADEN-7, 236–237, 238f, 248, 250–251  enterohepatic circulation, 52–54
          Cancer                              eukaryotic cells, 43
            chemotherapy, 84–85               gallbladder, 51–55, 59
            definition, 83                    human body, 45–47, 45f
            immunotherapy, 84–85              ischemic diseases, 43–44
            metastases, 83                    mathematical modeling, 44–45
            radiotherapy, 85                  metabolic pathways, 45f,46–47
          Cancer-immune system                parameter estimation, 50–51
            chemotherapy and control model, 89–93  pharmacological agents, 44–45
              external chemotherapy, 89–90, 90f  physiological levels, 57–58
              immuno-chemotherapy treatment, 89  steroid hormones, 43, 52
              optimal control theory, 89–91, 95–96  two-compartment model, 45, 47–50, 47f,
              optimality system, 92–93, 96       56–58, 56f
              Pontryagin’s maximum principle,  Cholesteryl ester transfer protein (CETP),
                90–92, 95–96                     47, 58
            mathematical models, 85–89      Chylomicron remnants (CR), 46
              boundedness and nonnegativity, 87–89  Chylomicrons (CM), 46, 56–57
              effector and tumor cells, interaction  CM. See Chylomicrons (CM)
                between, 86                 Coiled fibers, 319–320
              Gronwall lemma, 88            Compartmental modeling approach,
              ordinary/delay/partial differential  5–6, 7f
                equations, 85–87            Complex nonlinear dynamical
              time-delay (time-lag), 86–87, 95–96  systems, 64
            numerical simulations, 93–95    Computer aided design (CAD), 326
              Euler methods, forward and backward,  chiral structure, 329f
                93                            double arrowhead structure, 331f
              Pontryagin-type maximum principle,  of improved concept, 325f
                93                            missing rib design, drawing of, 330f
              of tumor and effector cells of system,  of proposed assembly, 324f
                94f,95                        re-entrant structure, 328f
            optimal control problem, 85       Star 4, drawing of, 329f
          Cardiac arrhythmia classification.  Continuous glucose measurement (CGM),
                See Arrhythmia classification    68–69
   396   397   398   399   400   401   402   403   404   405   406